1.3K(top 11%)
articles
80.3K(top 6%)
citations
575(top 7%)
★★ articles
64(top 4%)
★★★ articles
4.7(top 4%)
Avg IF
122(top 5%)
H-Index
262(top 4%)
G-Index
375
journals

Most Cited Articles of Alvin J. Siteman Cancer Center in 2018

TitleJournalYearCitations
Oncogenic Signaling Pathways in The Cancer Genome AtlasCell20181.1K
Comprehensive Characterization of Cancer Driver Genes and MutationsCell2018854
DGIdb 3.0: a redesign and expansion of the drug-gene interaction databaseNucleic Acids Research2018414
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome AtlasCell Reports2018405
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx RenalCell2018350
Pathogenic Germline Variants in 10,389 Adult CancersCell2018342
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic PipelinesCell Systems2018320
Driver Fusions and Their Implications in the Development and Treatment of Human CancersCell Reports2018235
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateEuropean Journal of Cancer2018179
Perspective on Oncogenic Processes at the End of the Beginning of Cancer GenomicsCell2018166
Systematic Analysis of Splice-Site-Creating Mutations in CancerCell Reports2018121
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung CancerJournal of Clinical Oncology2018120
Systematic Functional Annotation of Somatic Mutations in CancerCancer Cell2018114
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemiaBlood201883
Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent LymphomaCancer Discovery201878
Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell CarcinomaEuropean Urology201873
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic AnalysesCancer Cell201867
Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precisionJournal of Pathology201866
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaCancer Immunology Research201866
The prognostic effects of somatic mutations in ER-positive breast cancerNature Communications201851
Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data AnalysisClinical Breast Cancer201848
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerCell Reports201843
Metal–Organic Framework Encapsulation for Biospecimen PreservationChemistry of Materials201841
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasBlood201839
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 StudyBlood201838